Login to Your Account

In The Clinic NEWS

A long half-life, high bioavailability and no food affect – plus the prospect for add-back hormone therapy or not – may distinguish Obseva SA's GnRH therapy for UF and endometriosis.

Lack of a dose response across the three levels of drug tested in part A of the phase II/III turned out to be no big deal for Cara Therapeutics Inc.

Positive data from dual phase III studies of oral sarecycline in moderate to severe acne poised originator Paratek Pharmaceuticals Inc. to earn a $5 million milestone payment from partner Allergan plc.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: